Nov 24, 20212 min read

Merck and Dragonfly, Together Again

Nov 24, 20211 min read

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

Nov 24, 20211 min read

Merck hits 'go' on a second Dragonfly drug

Nov 23, 20211 min read

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Nov 23, 20212 min read

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Nov 9, 20213 min read

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

Oct 18, 20212 min read

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb

Jan 12, 20212 min read

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

Jan 12, 20211 min read

AbbVie selects target for Dragonfly partnership

Dec 10, 20202 min read

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

Dec 2, 20202 min read

Merck opts in for Dragonfly's TriNKET cancer immunotherapy program

Dec 1, 20202 min read

Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly

Nov 24, 20204 min read

Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer

Aug 17, 20202 min read

Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy

Aug 17, 20202 min read

Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly

Aug 16, 20202 min read

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License

Aug 16, 20202 min read

Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program

Aug 16, 20201 min read

Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology

Aug 9, 20202 min read

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET™ Immunotherapy Drug Candidate

Jul 6, 20202 min read

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

123